Hamilton Point Investment Advisors LLC Grows Stake in Amgen Inc. (NASDAQ:AMGN)

Hamilton Point Investment Advisors LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 35,214 shares of the medical research company’s stock after acquiring an additional 532 shares during the period. Amgen accounts for approximately 1.6% of Hamilton Point Investment Advisors LLC’s investment portfolio, making the stock its 17th biggest holding. Hamilton Point Investment Advisors LLC’s holdings in Amgen were worth $9,178,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP acquired a new stake in shares of Amgen in the 3rd quarter valued at about $25,000. Legacy Investment Solutions LLC purchased a new stake in Amgen in the third quarter valued at approximately $29,000. Matrix Trust Co acquired a new stake in shares of Amgen in the third quarter valued at approximately $36,000. Livelsberger Financial Advisory purchased a new position in shares of Amgen during the third quarter worth approximately $56,000. Finally, Icon Wealth Advisors LLC increased its holdings in shares of Amgen by 3,955.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 174,040 shares of the medical research company’s stock valued at $56,000 after acquiring an additional 169,748 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on AMGN shares. Bank of America reissued an “underperform” rating and set a $256.00 price objective on shares of Amgen in a research report on Tuesday, December 10th. Barclays boosted their price target on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Piper Sandler decreased their price objective on Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research report on Thursday, January 2nd. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Finally, Redburn Partners decreased their price target on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Amgen has an average rating of “Hold” and an average target price of $314.00.

Amgen Stock Performance

Shares of AMGN opened at $284.02 on Friday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The stock has a market cap of $152.67 billion, a P/E ratio of 36.37, a PEG ratio of 2.85 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The company has a 50-day moving average of $271.24 and a two-hundred day moving average of $304.84.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.96 EPS. As a group, research analysts predict that Amgen Inc. will post 19.56 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.35%. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s payout ratio is 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.